miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways

xlomafota13 shared this article with you from Inoreader miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways Via Experimental and therapeutic medicine Exp Ther Med. 2022 Jan;23(1):98. doi: 10.3892/etm.2021.11021. Epub 2021 Dec 1. ABSTRACT Prostate cancer occurs in the prostatic epithelium and poses a threat to the health of middle-aged and older males. The objective of the present study was to explore the roles of microRNA (miRNA/miR)-130b in prostate cancer and potential molecular mechanisms in order to control the migration and invasion of prostate cancer. For this purpose, reverse transcription-PCR was performed to evaluate the mRNA levels of DLL1, phosphoinositide-3 kinase (PI3K), protein kinase B (Akt) and matrix metalloproteinase (MMP)9, and western blot analysis was carried out to detect the protein expression levels of DLL1, phosphorylated (p)-PI3K, p-Akt and MMP9. A Transwell assay was conducted to examine the invasion rate of prostate cancer cells. Furthermore, a scratch wound assay was performed to examine the migration rate of prostate cancer cells. A luciferase assay was performed to examine the interaction between miRNA and its target mRNA. The results revealed that miR-130b had abnormal (low) expression in tumor tissues compared with that in the adjacent normal tissue. An miR-130b mimic suppressed the expression of DLL1. The expression of p-PI3K, p-Akt and MMP9 in prostate cancer cells transfected with the miR-130b mimic was decreased in comparison to the negative control and control groups. Furthermore, migration and invasion were significantly suppressed in the miR-130b mimic group. In conclusion, a novel pathway interlinking miR-130b and MMP9, p-Akt and p-PI3K, which regulates the migration and invasion of prostate cancer cells, was identified. These findings provide an intriguing biomarker and treatment strategy for patients with prostate cancer. PMID:34976140 | PMC:PMC8674980 | DOI:10.3892/etm.2021.11021 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.